The Artificial Pancreas is Finally Coming to Market

According to a story in Tuesday’s USA Today, the first artificial pancreas systems are beginning to come to market.

The artificial pancreas is a nickname given to wearable devices that take on the dual task of monitoring glucose levels as well as administering insulin. Also referred to as a “closed-loop” system because  the devices do their work with no help from humans.

The first system to hit the market is the MiniMed 670G from Medtronic. Other companies have active studies underway and hope to bring their products to the marketplace later this year or in 2018. Those companies include startup Bigfoot Biomedical, Insulet, and a partnership between Dexcom, Tandem, and TypeZero.

The article states that these systems actually aren’t an option for most diabetes, many of whom have type 2 diabetes. The artificial pancreas is for the 10% of diabetes patients who have type 1 diabetes.

Read the entire article at USA Today.

You may also like

  • Researchers Studying Novel Gestational Diabetes Screening Alternative

    Researchers at Brigham and Women’s Hospital (BWH) recently published a study demonstrating the potential clinical utility of glycated CD59 (GCD59) as a novel biomarker for the screening and diagnosis of gestational diabetes mellitus (GDM). The data from this study showed that a single blood test that measures plasma GCD59 at week 24-28 of gestation identified…

  • Personalized Insulin Dosing Could Lead to Better Outcomes Following CABG Surgery

    A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay, and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less…